Evidence map›Paper›PMID 31162826›Full record

ArticleChemMedChem2019

Synthesis and Study of Multifunctional Cyclodextrin-Deferasirox Hybrids.

Jose Miguel Gascon, Valentina Oliveri, Andrew McGown, Ecem Kaya, Yu-Lin Chen, Carol Austin, Martin Walker, Frances M Platt, Graziella Vecchio, John Spencer

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Jose Miguel GasconDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer, Brighton, East Sussex, BN1 9QJ, UK.ORCID 0000-0002-3982-0319
Valentina OliveriDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer, Brighton, East Sussex, BN1 9QJ, UK.ORCID 0000-0001-7603-4790
Andrew McGownDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer, Brighton, East Sussex, BN1 9QJ, UK.
Ecem KayaDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK.
Yu-Lin ChenPharmaceutical Science, King's College London, Franklin Wilkins Building, London, SE1 9NH, UK.ORCID 0000-0001-9710-4436
Carol AustinEurofins Selcia Drug Discovery, Fyfield Business & Research Park, Fyfield Road, Ongar, Essex, CM5 0GS, UK.
Martin WalkerEurofins Selcia Drug Discovery, Fyfield Business & Research Park, Fyfield Road, Ongar, Essex, CM5 0GS, UK.
Frances M PlattDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK.ORCID 0000-0001-7614-0403
Graziella VecchioDipartimento di Scienze Chimiche, Università degli Studi di Catania, Viale A. Doria 6, 95125, Catania, Italy.ORCID 0000-0001-8305-081X
John SpencerDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer, Brighton, East Sussex, BN1 9QJ, UK.ORCID 0000-0001-5231-8836
University of Sussex · GBDiscovery Centre · CAMansfield University · USKing's College London · GBUniversity of Catania · IT

Funding

Wellcome Trust
6 · The paper itself

Abstract

Metal dyshomeostasis is central to a number of disorders that result from, inter alia, oxidative stress, protein misfolding, and cholesterol dyshomeostasis. In this respect, metal deficiencies are usually readily corrected by treatment with supplements, whereas metal overload can be overcome by the use of metal-selective chelation therapy. Deferasirox, 4-[(3Z,5E)-3,5-bis(6-oxo-1-cyclohexa-2,4-dienylidene)-1,2,4-triazolidin-1-yl]benzoic acid, Exjade, or ICL670, is used clinically to treat hemosiderosis (iron overload), which often results from multiple blood transfusions. Cyclodextrins are cyclic glucose units that are extensively used in the pharmaceutical industry as formulating agents as well as for encapsulating hydrophobic molecules such as in the treatment of Niemann-Pick type C or for hypervitaminosis. We conjugated deferasirox, via an amide coupling reaction, to both 6

Indexed as

alpha-SynucleinAnimalsAntioxidantsCHO CellsCricetulusCyclodextrinsDeferasiroxHep G2 CellsHumansIron Chelating AgentsProtein Multimerizationalpha-SynucleinAntioxidantsCyclodextrinsDeferasiroxIron Chelating Agentsantioxidantdeferasiroxiron complexesNiemann-Pickprotein aggregation

Identifiers

PMID31162826
PMCPMC6771688
OpenAlexW2948996326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.